ID   WERI-Rb-1 Eto-R
AC   CVCL_B7ID
SY   WERI-Rb1 etoposide-resistant; WERI-Rb1 Etop; WERI-ETOR
DR   PRIDE; PXD030924
DR   Wikidata; Q112930565
RX   PubMed=29192327;
RX   PubMed=35409416;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16).
CC   Omics: Deep quantitative proteome analysis.
CC   Derived from site: In situ; Eye, globe; UBERON=UBERON_0010230.
DI   NCIt; C7541; Retinoblastoma
DI   ORDO; Orphanet_790; Retinoblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1792 ! WERI-Rb-1
SX   Female
AG   1Y
CA   Cancer cell line
DT   Created: 23-06-22; Last updated: 29-06-23; Version: 4
//
RX   PubMed=29192327; DOI=10.3892/or.2017.6100;
RA   Busch M.A., Papior D., Stephan H., Dunker N.;
RT   "Characterization of etoposide- and cisplatin-chemoresistant
RT   retinoblastoma cell lines.";
RL   Oncol. Rep. 39:160-172(2018).
//
RX   PubMed=35409416; DOI=10.3390/ijms23074058;
RA   Kakkassery V., Gemoll T., Kraemer M.M., Sauer T., Tura A., Ranjbar M.,
RA   Grisanti S., Joachim S.C., Mergler S., Reinhard J.;
RT   "Protein profiling of WERI-RB1 and etoposide-resistant WERI-ETOR reveals
RT   new insights into topoisomerase inhibitor resistance in retinoblastoma.";
RL   Int. J. Mol. Sci. 23:4058.1-4058.14(2022).
//